Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind,...

Keywords

MedicineTolerabilityPlaceboVaccinationCohortClinical trialInternal medicineRandomized controlled trialAdverse effectImmunologyPathology

Affiliated Institutions

Related Publications

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti , Katie Ewer , Parvinder K. Aley +97 more

2020 The Lancet 2590 citations

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Meagan Bolles , Meagan E. Deming , Kristin A. Long +8 more

ABSTRACT Severe acute respiratory syndrome coronavirus (SARS-CoV) is an important emerging virus that is highly pathogenic in aged populations and is maintained with great diver...

2011 Journal of Virology 500 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Publication Info

Year: 2020
Type: article
Volume: 21
Issue: 2
Pages: 181-192
Citations: 1488
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1488

OpenAlex

Cite This

APA Style

                            
                                
                                    Yanjun Zhang, 
                                
                                    Gang Zeng, 
                                
                                    Hongxing Pan
                                
                                et al.
                            
                            (2020). 
                            Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. 
                            The Lancet Infectious Diseases
                            , 21
                            (2)
                            , 181-192.
                            https://doi.org/10.1016/s1473-3099(20)30843-4
                        

Identifiers

DOI: 10.1016/s1473-3099(20)30843-4